抗宫炎片联合重组人干扰素α2b凝胶治疗慢性宫颈炎的效果

Abstract
Figure/Table
References (24)
Related Citation (15)

Download: PDF (373 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical efficacy of Kanggongyan Tablets combined with Recombinant Human Interferon α2b Gel in the treatment of chronic cervicitis. Methods From March 2018 to June 2019, 198 cases of chronic cervicitis who admitted to Liaoning Health Industry Group Fuxin Mine General Hospital were selected. They were divided into control group (n = 99, Recombinant Human Interferon α2b Gel treatment) and study group (n = 99, Kanggongyan+Recombinant Human Interferon α2b Gel treatment) according to the random number table method. The course of treatment was 2 weeks. The clinical efficacy, immunoglobulin (Ig) M, IgG, IgA, hypersensitive C-reactive protein (hs-CRP), interleukin-10 (IL-10) and vascular endothelial growth factor (VEGF), natural killer T cells (NKTs) of two groups were compared, and the adverse reactions were recorded. Results The total clinical effective rate of study group was significantly higher than that of control group (P < 0.05). There was no significant difference in the indexes of immune function between two groups before treatment (P > 0.05). After treatment, the levels of IgM, IgG and IgA in two groups were higher than those before treatment, and study group was higher than control group (P < 0.05). There was no significant difference in serum inflammatory factors and cytokines between two groups before treatment (P > 0.05). After treatment, the levels of hs-CRP, IL-10 and VEGF in two groups were lower than those before treatment, and study group was lower than control group (P < 0.05), the level of NKTs was higher than that before treatment, and study group was higher than control group (P < 0.05). There was no difference in the total incidence of adverse reactions between two groups (P > 0.05). Conclusion Kanggongyan Tablets combined with Recombinant Human Interferon α2b Gel are effective in treating chronic cervicitis. It can significantly improve immune function, reduce inflammatory reaction, and has a high safety. Clinical treatment can be used for reference.

Key words： Chronic cervicitis Kanggongyan Tablets Recombinant Human Interferon α2b Gel Efficacy Inflammatory factor

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHOU Rui GAO Yanhong TIAN Mengdie

Cite this article:

ZHOU Rui GAO Yanhong TIAN Mengdie. Effect of Kanggongyan Tablets combined with Recombinant Human Interferon α2b Gel in the treatment of chronic cervicitis[J]. 中国医药导报, 2020, 17(8): 97-100.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I8/97

[1] Hester EE，Middleman AB. A Clinical Conundrum：Chronic Cervicitis [J]. J Pediatr Adolesc Gynecol，2019，32（3）：342-344.
[2] Acosta-Rios MP，Sauer-Ramírez E，Castro-Mu?觡oz LJ，et al. Effect of Dialyzable Leukocyte Extract on chronic cervicitis in patients with HPV infection [J]. J Med Life，2017， 10（4）：237-243.
[3] 曹悦明.干扰素α-2b栓联合复方沙棘籽油栓治疗慢性宫颈炎伴高危型乳头瘤病毒感染疗效观察[J].现代中西医结合杂志，2017，26（20）：2246-2248.
[4] 胡静.重组人干扰素α-2b凝胶治疗慢性宫颈炎的临床疗效[J].中国妇幼保健，2016，31（10）：2076-2077.
[5] 郑声秀.聚甲酚磺醛联合抗宫炎片治疗宫颈糜烂疗效观察[J].临床医药文献电子杂志，2016，3（6）：1151，1154.
[6] 石磬，肖瑾，陈磊.抗宫炎片治疗慢性宫颈炎142例疗效分析[J].甘肃中医，2001，14（4）：53-54.
[7] 谢幸，苟文丽.妇产科学[M].8版.北京：人民卫生出版社，2013：255-256.
[8] 孙传兴.临床疾病诊断依据治愈好转标准-2[M].北京：人民军医出版社，2002：530-531.
[9] Kumar A. Chronic Cervicitis [J]. J Minim Invasive Gynecol，2018，25（1）：4-5.
[10] Mattson SK，Polk JP，Nyirjesy P. Chronic Cervicitis：Presenting Features and Response to Therapy [J]. J Low Genit Tract Dis，2016，20（3）：e30-e33.
[11] 李华梅，黄春优.慢性宫颈炎的临床特征及相关危险因素分析[J].中国医药科学，2019，9（22）：99-101，179.
[12] 司百会，刘海霞，司凡，等.宫颈疾病患者HPV感染分型及微量元素检测分析[J].中国医药导报，2019，16（30）：106-109.
[13] 马宝满，韦育红，梁素梅，等.内服外敷中药联合电波刀治疗慢性宫颈炎的临床疗效观察[J].河北医学，2017， 23（11）：1929-1931.
[14] 国家药典委员会.中国药典[M].一部.北京：中国医药科技出版社，2015：1283-1284.
[15] 唐春莲，房敏.聚甲酚磺醛栓联合抗宫炎片治疗宫颈糜烂的临床效果观察[J].包头医学院学报，2015，31（8）：55-56.
[16] 施月英.聚甲酚磺醛栓联合抗宫炎片治疗宫颈糜烂的临床疗效评价[J].大家健康：中旬版，2016，10（3）：222.
[17] 张平.重组人干扰素α-2b对慢性宫颈炎合并HPV感染患者炎症因子水平及免疫功能的影响[J].中国民康医学，2018，30（14）：40-41.
[18] 陈晓燕，冉华阳，张锦安，等.益母草浸膏对产后子宫内膜炎作用功效的实验研究[J].中国中医急症，2017，26（1）：50-52，64.
[19] 叶荣珠.探讨重组人干扰素α-2b凝胶治疗慢性宫颈炎的临床疗效[J].海峡药学，2017，29（9）：125-126.
[20] 张宏艳，黄丹维.LEEP刀和重组人干扰素α-2b凝胶联合应用于慢性宫颈炎治疗中对疗效、感染率及创面愈合率的影响[J].中外医学研究，2019，17（3）：133-134.
[21] 王新玲，李昭昭，古扎丽努尔·阿不力孜，等.维吾尔族宫颈病变中VEGF-C与HPV相关性研究[J].重庆医学，2016，45（23）：3173-3175.
[22] 麦艳芬，吴叶欢，周瑞芳，等.慢性宫颈炎患者自然杀伤T细胞与炎症分度的关系[J].分子影像学杂志，2014， 37（3）：184-185，196.
[23] 高音，冯晓萍.聚甲酚磺醛栓联合抗宫炎片治疗宫颈柱状上皮异位的临床效果观察[J].中国性科学，2015，24（2）：32-34.
[24] 霍艳芬，霍墨杰，苏俊泽，等.重组人干扰素α-2b凝胶联合乳酸菌阴道胶囊治疗高危型人乳头瘤病毒感染的临床观察[J].中国计划生育和妇产科，2018，10（5）：45-48.